-+ 0.00%
-+ 0.00%
-+ 0.00%

INTELLIA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 MAGNITUDE-2 TRIAL OF NEXIGURAN ZICLUMERAN (NEX-Z) FOR PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY (ATTRV-PN)

Reuters·11/04/2026 13:00:02

Please log in to view news